Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds. It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014, becoming the first approved therapy against PD-1. In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers.
Pembrolizumab is indicated for the following conditions:
For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Columbia University / Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Box Hill Hospital, Melbourne, Victoria, Australia
Chris O'Brien Lifehouse, Sydney, New South Wales, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
City of Hope, Duarte, California, United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Mayo Clinic, Rochester, Minnesota, United States
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
University of Colorado, Denver, Colorado, United States
The Royal Marsden NHS Foundation Trust, London, England, United Kingdom
University of Southern California, Los Angeles, California, United States
The University of Kansas Cancer Center, Overland Park Clinic, Overland Park, Kansas, United States
Texas Oncology- Baylor, Dallas, Texas, United States
The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
M D Anderson Cancer Center, Houston, Texas, United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
John Wayne Cancer Institute - Providence Saint John's Health Center, Santa Monica, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
Duke University, Durham, North Carolina, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.